Letters to the Editor
Vol. 14 No. 2 (2020)
https://doi.org/10.4081/itjm.2020.1290
Antirheumatic in SARS-CoV-2: benefit or risk?
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Received: 15 April 2020
Published: 29 April 2020
Published: 29 April 2020
2230
Views
719
Downloads
9
HTML
Not available
Downloads
Download data is not yet available.
How to Cite
Antirheumatic in SARS-CoV-2: benefit or risk? (2020). Italian Journal of Medicine, 14(2), 114-115. https://doi.org/10.4081/itjm.2020.1290
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.